Life Technologies acquired Netherlands-based BAC, which is involved in the discovery, development, and manufacture of protein purification products. The acquisition expands Life’s capabilities and product offerings in the growing market of biopharmaceutical research and manufacturing, according to a Life Technologies official.
“Our acquisition of BAC BV positions Life Technologies as a leading provider of end-to-end solutions that are widely utilized in the bioprocess workflow,” explained Tony Hunt, head of bioproduction at Life Tech. “Combining BAC’s current portfolio and pipeline with our pre-existing portfolio expands Life’s product offering and enables us to compete more fully across the protein purification market.”
Life Technologies’ Gibco® brand is targeted at the cell culture media market, and the company more recently integrated its Poros® brand of chromatography resins for purification of therapeutic products into the bioproduction portfolio. Hunt noted that the acquisition expands Life’s existing portfolio by adding BAC’s affinity ligands to the Poros resins. Life also offers the Applied Biosystems® SEQ molecular kits for contaminant and impurity testing of biotherapeutic products, added Hunt.
It’s been estimated that downstream processing and purification activities are responsible for up to 60% of the entire production cost.